Skip to main content
. 2014 May 6;22(7):1254–1265. doi: 10.1038/mt.2014.59

Figure 5.

Figure 5

Inhibition of the hIL-6 signaling pathway by hIL-6-specific repebodies. (a) H1650 cells were incubated with different repebodies at varying amounts (0.1, 1, 10 μg/ml), along with anti-IL-6 mAb (Ab) or an isotype control (IC) (1 μg/ml). H1650 cells were incubated for 18 hours for an immunoblot analysis of the phosphorylated and total form of STAT3 (upper), or for analysis of hIL-6 using ELISA (lower). The data represent the mean and standard deviations from the triplicate experiments. *P < 0.05; **P < 0.01; ***P < 0.001 compared with the solvent control (SC). SC indicates the solvent control (0.1% DMSO). The experiments were carried out seven times. (b) Death of non–small cell lung cancer (NSCLC) cells by various repebodies. H1650 cells were incubated with each repebody (1 μg/ml), αIL-6 mAb (Ab) or an isotype control (IC; 1 μg/ml) for the indicated time periods, and MTT assays were conducted on NSCLC cells. The data indicate the mean ± SD in triplicate experiments. SC indicates a solvent control (0.1% DMSO). DMSO, dimethyl sulfoxide.